MedTrace Logo

Phase I/II Study of COVID-19 DNA Vaccine (AG0302-COVID19 High-dose)

NCT04993586 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 422

Last updated 2022-11-09

No results posted yet for this study

Summary

This study will assess the safety and immunogenicity of AG0302-COVID19 in healthy volunteers.

Conditions

  • COVID-19 Lower Respiratory Infection

Interventions

BIOLOGICAL

AG0302-COVID19 for Intramuscular Injection

Vaccination 2 mg of AG0302-COVID19 three times at 2-week intervals

BIOLOGICAL

AG0302-COVID19 for Intramuscular Injection

Vaccination 4 mg of AG0302-COVID19 twice at 4-week intervals

BIOLOGICAL

AG0302-COVID19 for Intramuscular Injection

Vaccination 8 mg of AG0302-COVID19 twice at 4-week intervals

BIOLOGICAL

AG0302-COVID19 for Intradermal Injection

Vaccination 1 mg of AG0302-COVID19 three times at 2-week intervals

BIOLOGICAL

AG0302-COVID19 for Intradermal Injection

Vaccination 1 mg of AG0302-COVID19 twice at 4-week intervals

Sponsors & Collaborators

  • Japan Agency for Medical Research and Development

    collaborator OTHER_GOV

  • AnGes, Inc.

    lead INDUSTRY

Principal Investigators

  • Clinical Development · AnGes, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-07-29
Primary Completion
2021-12-10
Completion
2022-09-23

Countries

  • Japan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04993586 on ClinicalTrials.gov